EBOS Group (ASX:EBO) - Stock Price, News & Analysis

EBO Stock Overview

EBOS Group Limited se dedica a la comercialización, venta al por mayor y distribución de productos sanitarios, médicos, farmacéuticos y para el cuidado de los animales en Australia, Nueva Zelanda y el Sudeste Asiático.

About the company

EBO fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	4/6
Financial Health	5/6
Dividends	4/6

Rewards

Cotiza un 31.4% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 6.1%

Los beneficios aumentaron un 10.5% el año pasado

Risk Analysis

Tiene un alto nivel de endeudamiento

El dividendo de 3.05% no está bien cubierto por los flujos de caja

Venta significativa de accionistas con acceso a información confidencial en los últimos 3 meses

EBOS Group Limited Competitors

Paragon Care

ASX:PGC

AU$217.1m

Ramsay Health Care

ASX:RHC

AU$12.4b

Sonic Healthcare

ASX:SHL

AU$13.9b

Pro Medicus

ASX:PME

AU$11.0b

Price History & Performance

Summary of all time highs, changes and price drops for EBOS Group
Historical stock prices
Current Share Price	NZ$31.67
52 Week High	NZ$43.08
52 Week Low	NZ$30.81
Beta	0.26
1 Month Change	-6.41%
3 Month Change	-6.74%
1 Year Change	-25.83%
3 Year Change	15.92%
5 Year Change	58.35%
Change since IPO	281.57%

Recent updates

Shareholder Returns

	EBO	AU Healthcare	AU Market
7D	-0.06%	-3.0%	-1.5%
1Y	-25.8%	-19.6%	8.5%

Rentabilidad frente al sector: EBO obtuvo unos resultados inferiores a los del sector Australian Healthcare , que el año pasado arrojó un rendimiento del -16.6%.

Rentabilidad vs. Mercado: EBO obtuvo unos resultados inferiores a los del mercado Australian, que fue del 4.3% el año pasado.

Price Volatility

Is EBO's price volatile compared to industry and market?
EBO volatility
EBO Average Weekly Movement	3.0%
Healthcare Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.3%

Precio estable de las acciones: EBO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EBO (4%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1922	5,000	John Cullity	https://www.ebosgroup.com

EBOS Group Limited se dedica a la comercialización, venta al por mayor y distribución de productos sanitarios, médicos, farmacéuticos y para el cuidado de animales en Australia, Nueva Zelanda y el Sudeste Asiático. Opera a través de los segmentos Healthcare y Animal Care. La empresa ofrece servicios de logística sanitaria; soluciones de gestión de medicamentos; software de gestión de farmacias; servicios de fidelización, genéricos, cumplimiento, inteligencia empresarial y software para tiendas; y servicios de comunicación, programas y consultoría en materia de salud.

EBOS Group Limited Fundamentals Summary

How do EBOS Group's earnings and revenue compare to its market cap?
EBO fundamental statistics
Market cap	AU$6.12b
Earnings (TTM)	AU$257.35m
Revenue (TTM)	AU$12.67b

23.8x

P/E Ratio

0.5x

P/S Ratio

Is EBO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EBO income statement (TTM)
Revenue	AU$12.67b
Cost of Revenue	AU$11.09b
Gross Profit	AU$1.58b
Other Expenses	AU$1.33b
Earnings	AU$257.35m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 21, 2024

Earnings per share (EPS)	1.33
Gross Margin	12.49%
Net Profit Margin	2.03%
Debt/Equity Ratio	62.3%

How did EBO perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

78%

Payout Ratio

EBO Stock Overview

Rewards

Risk Analysis

EBOS Group Limited Competitors

ASX:PGC

AU$217.1m

ASX:RHC

AU$12.4b

ASX:SHL

AU$13.9b

ASX:PME

AU$11.0b

Price History & Performance

Recent News & Updates

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

Recent updates

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorates as stock falls 17%

Now 26% undervalued after recent price drop

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

Price target increased to AU$31.66

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Price target raised to AU$25.70

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

Revenue beats expectations

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$27.92

New 90-day high: AU$25.25

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.26

New 90-day high - AU$21.38

Full year earnings released - EPS AU$1.01

New 90-day low - AU$20.00